Evidence map›Paper›PMID 39011356›Full record

ArticleJournal of pharmaceutical policy and practice2024

The pharmacists' interventions after a Drug and Therapeutics Committee (DTC) establishment during the COVID-19 pandemic.

Amira B Kassem, Ahmad Z Al Meslamani, Dina H Elmaghraby, Yosr Magdy, Mohamed AbdElrahman, Ahmed M E Hamdan, Hebatallah Ahmed Mohamed Moustafa

Abstract read
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amira B KassemDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.ORCID https://orcid.org/0000-0003-4195-6036
Ahmad Z Al MeslamaniCollege of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates.
Dina H ElmaghrabyKafr El Dawar General Hospital, Department of infectious disease, Ministry of Health, Beheira, Egypt.
Yosr MagdyKafr El Dawar General Hospital, Department of infectious disease, Ministry of Health, Beheira, Egypt.
Mohamed AbdElrahmanClinical Pharmacy Department, College of Pharmacy, Al-Mustaqbal University, Babylon, Iraq.
Ahmed M E HamdanDepartment of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
Hebatallah Ahmed Mohamed MoustafaClinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Badr University in Cairo, Badr, Egypt.ORCID https://orcid.org/0000-0003-4530-406X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Healthcare systems in developing countries faced significant challenges during COVID-19, grappling with limited resources and staffing shortages. Assessment of the impact of pharmaceutical care expertise, particularly in critical care units during the pandemics, in developing countries remains poorly explored. The principal aim of our study was to assess the impact of the Drug and Therapeutics Committee (DTC), comprising clinical pharmacists, on the incidence, types, and severity of medication errors and associated costs in using COVID-19 medications, especially antibiotics. Methods: An interventional pre-post study was carried out at a public isolation hospital in Egypt over 6 months. Results: Out of 499 medication orders, 238 (47.7%) had medication errors, averaging 2.38 errors per patient. The most frequent were prescribing errors (44.9%), specifically incorrect drug choice (57.9%), excessive dosage (29.9%), treatment duplication (4.5%), inadequate dosage (4.5%), and overlooked indications (3.6%). Linezolid and Remdesivir were the most common medications associated with prescribing errors. Pharmacists intervened 315 times, primarily discontinuing medications, reducing doses, introducing new medications, and increasing doses. These actions led to statistically significant cost reductions ( Conclusion: Crucially, educational initiatives targeting clinical pharmacists can foster judicious prescribing habits.

Indexed as

Antibiotics abuseclinical pharmacistsCOVID-19Drug and Therapeutics Committeeintensive care unitmedication errors

Identifiers

PMID39011356
PMCPMC11249153

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.